KPC PHARMACEUTICALS, INC. — Investor Relations & Filings
About KPC PHARMACEUTICALS, INC.
KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 昆药集团2025年度独立董事述职报告(王桂华) | 2026-03-19 | Chinese | |
| 昆药集团2025年度审计报告 | 2026-03-19 | Chinese | |
| 昆药集团对2025年度会计师事务所履职情况的评估报告 | 2026-03-19 | Chinese | |
| 昆药集团董事会审计与风险控制委员会对会计师事务所2025年度履行监督职责情况的报告 | 2026-03-19 | Chinese | |
| 昆药集团2025年度审计与风险控制委员会履职报告 | 2026-03-19 | Chinese | |
| 昆药集团2025年度业绩快报 | 2026-02-06 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
10 filings
| |||||
| 40930177 | 昆药集团2025年度独立董事述职报告(王桂华) | 2026-03-19 | Chinese | ||
| 40930165 | 昆药集团2025年度审计报告 | 2026-03-19 | Chinese | ||
| 40930045 | 昆药集团对2025年度会计师事务所履职情况的评估报告 | 2026-03-19 | Chinese | ||
| 40930044 | 昆药集团董事会审计与风险控制委员会对会计师事务所2025年度履行监督职责情况的报告 | 2026-03-19 | Chinese | ||
| 40930031 | 昆药集团2025年度审计与风险控制委员会履职报告 | 2026-03-19 | Chinese | ||
| 40930021 | 昆药集团2025年度业绩快报 | 2026-02-06 | Chinese | ||
| 40930014 | 昆药集团关于董事离任的公告 | 2026-01-07 | Chinese | ||
| 40930003 | 昆药集团十一届十四次董事会决议公告 | 2026-01-05 | Chinese | ||
| 40929993 | 昆药集团关于董事长变更的公告 | 2026-01-05 | Chinese | ||
| 40929980 | 昆药集团关于高级管理人员变更的公告 | 2026-01-05 | Chinese | ||
|
2025
5 filings
| |||||
| 40929977 | 昆药集团股份有限公司内幕信息知情人管理制度(2025年12月修订) | 2025-12-30 | Chinese | ||
| 40929966 | 昆药集团股份有限公司信息披露暂缓与豁免业务管理制度(2025年12月修订) | 2025-12-30 | Chinese | ||
| 40929954 | 昆药集团股份有限公司总裁工作细则(2025年12月修订) | 2025-12-30 | Chinese | ||
| 40929946 | 昆药集团股份有限公司董事会授权管理制度(2025年12月修订) | 2025-12-30 | Chinese | ||
| 40929931 | 昆药集团股份有限公司信息披露管理制度(2025年12月修订) | 2025-12-30 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
KPC PHARMACEUTICALS, INC. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/56720/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=56720 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=56720 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=56720 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 56720}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for KPC PHARMACEUTICALS, INC. (id: 56720)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.